Consequently, UCHL1 may serve as disease biomarker as well as a potential novel therapeutic target for breast cancers with loss or reduction of ER expression; however, it may not be a suitable target for HER2+ breast cancers, which typically have low endogenous UCHL1 expression [41]. Here, ESR1 is linked to breast carcinoma.